Business Insider
My Markets Watchlist
Markets Stocks

Syndax Pharmaceuticals Inc Stock , SNDX

9.03 -0.26 -2.85%
03:59:59 PM EDT 6/27/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday 06/27/2025 the closing price of the Syndax Pharmaceuticals Inc share was $9.29 on BTT. Compared to the opening price on Friday 06/27/2025 on BTT of $9.38, this is a drop of 0.97%. Syndax Pharmaceuticals Inc's market capitalization is $622.53 M by 86.05 M shares outstanding.
Is Syndax Pharmaceuticals stock a Buy, Sell or Hold? Syndax Pharmaceuticals stock has received a consensus rating of buy. The average rating score is and is based on 33 buy ratings, 0 hold ratings, and 0 sell ratings.
What was the 52-week low for Syndax Pharmaceuticals stock? The low in the last 52 weeks of Syndax Pharmaceuticals stock was 8.58. According to the current price, Syndax Pharmaceuticals is 105.19% away from the 52-week low.
What was the 52-week high for Syndax Pharmaceuticals stock? The high in the last 52 weeks of Syndax Pharmaceuticals stock was 25.07. According to the current price, Syndax Pharmaceuticals is 36.00% away from the 52-week high.
What are analysts forecasts for Syndax Pharmaceuticals stock? The 33 analysts offering price forecasts for Syndax Pharmaceuticals have a median target of 38.52, with a high estimate of 51.00 and a low estimate of 29.00. The median estimate represents a 23.43 difference from the last price of 9.03.

Syndax Pharmaceuticals Stock Snapshot

7.81
Bid
100.00
Bid Size
10.29
Ask
100.00
Ask Size
6/27/2025
Date
3:59 PM
Time
96,362.00
Volume
9.29
Prev. Close
9.38
Open
777.87 M
Market Cap in USD
86.05 M
Number of Shares
86.05 M
Total Number of Shares
9.02
Day Low
9.40
Day High
9.03
8.58
52 Week Low
25.07
52 Week High
9.03
0.00
Dividend in USD
0.00
Dividend Yield
95.84
Free Float in %
-3.72
EPS in USD
3.36
Book Value per Share in USD
-3.21
Cash Flow per Share in USD

Historical Prices for Syndax Pharmaceuticals

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Syndax Pharmaceuticals Analyst Data

Total Analysts: 33
Buy Ratings: 33 Neutral Ratings: 0 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 29.00 Median: 38.52 Highest: 51.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Syndax Pharmaceuticals Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
05/06/25 Guggenheim
Maintained Buy $32
03/20/25 J.P. Morgan
Maintained Buy $41
03/04/25 J.P. Morgan
Maintained Buy $39
03/04/25 Citigroup Corp.
Maintained Buy $42
03/04/25 H.C. Wainwright & Co.
Maintained Buy $51
07/29/24 H.C. Wainwright & Co.
Maintained Buy $41
06/28/24 Jefferies & Company Inc.
Maintained Buy $37
06/26/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $42
06/17/24 H.C. Wainwright & Co.
Maintained Buy $41
06/06/24 H.C. Wainwright & Co.
Maintained Buy $41
05/21/24 J.P. Morgan
Maintained Buy $34
05/09/24 Citigroup Corp.
Maintained Buy $30
05/09/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $40
05/09/24 H.C. Wainwright & Co.
Maintained Buy $41
04/26/24 H.C. Wainwright & Co.
Maintained Buy $41
03/27/24 H.C. Wainwright & Co.
Maintained Buy $41
03/20/24 J.P. Morgan
Maintained Buy $34
02/28/24 H.C. Wainwright & Co.
Maintained Buy $41
01/02/24 H.C. Wainwright & Co.
Maintained Buy $41
12/22/23 H.C. Wainwright & Co.
Maintained Buy $41
12/22/23 Mizuho
Maintained Buy $45
10/26/23 Stifel, Nicolaus & Co., Inc.
Maintained Buy $36
10/25/23 Bank of America Merrill Lynch
Maintained Buy $29
10/17/23 J.P. Morgan
Maintained Buy $38
10/11/23 Goldman Sachs
Maintained Buy $30
10/02/23 H.C. Wainwright & Co.
Maintained Buy $42
08/16/23 J.P. Morgan
Maintained Buy $33
08/04/23 H.C. Wainwright & Co.
Maintained Buy $38
07/26/23 Citigroup Corp.
Maintained Buy $35
07/26/23 Barclays Capital
Maintained Buy $34
07/25/23 Guggenheim
Maintained Buy $42
07/24/23 H.C. Wainwright & Co.
Maintained Buy $38
07/11/23 Guggenheim
Maintained Buy $40

Syndax Pharmaceuticals Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 125 275 468 646 804
Dividend 0.00 0.00 0.00 - -
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % - -
EPS -3.76 -2.67 -1.42 -1.31 0.37
P/E Ratio -2.40 -3.38 -6.38 -6.89 24.75
EBIT -319 -216 -81 44 186
EBITDA -336 -196 -79 - -
Net Profit -320 -223 -91 26 166
Net Profit Adjusted -313 -187 6 330 552
Pre-Tax Profit -320 -223 -95 30 178
Pre-Tax Profit Reported -296 -249 -131 153 -
EPS (Non-GAAP) ex. SOE -3.49 -2.02 -0.02 3.18 5.14
EPS (GAAP) -3.76 -2.67 -1.42 -1.31 0.37
Gross Income 109 246 485 931 1,251
Cash Flow from Investing 147 200 0 0 0
Cash Flow from Operations -172 -146 -75 -63 -50
Cash Flow from Financing 6 9 10 14 16
Cash Flow per Share -2.56 -1.60 0.19 - -
Free Cash Flow -95 -142 -55 - -
Free Cash Flow per Share - - - - -
Book Value per Share 1.34 2.63 -0.79 - -
Net Debt 92 -36 212 - -
Research & Development Exp. 270 292 318 312 342
Capital Expenditure 2 3 3 0 0
Selling, General & Admin. Exp. 157 178 197 214 228
Shareholder’s Equity 90 322 103 457 453
Total Assets 576 742 554 831 789
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 11 11 11 11
Average Estimate - -1.000 USD -0.921 USD -3.763 USD -2.672 USD
Year Ago - -0.798 USD -0.985 USD -3.723 USD -
Publish Date - 8/11/2025 11/11/2025 - -
Revenue Estimates
No. of Analysts - 11 11 11 11
Average Estimate - 27 USD 34 USD 125 USD 275 USD
Year Ago - 4 USD 13 USD 24 USD -
Publish Date - 8/11/2025 11/11/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 23.68 0.00 0.00 139.71 1.52 1.52 1.52
Change of sales in % - - -100.00 9,109.56 0.00 0.00 -28.04
Gross profit on sales 22.85 -0.01 -0.45 139.25 - - -
Gross profit on sales change in % - 97.36 - - - - -
Operating income -339.67 -229.95 -151.76 26.22 -71.42 -57.54 -75.88
Operating income change in % -47.71 -51.53 - - -24.13 24.17 -22.47
Income before tax -318.76 -209.36 -149.34 24.93 -73.16 -56.05 -73.96
Income before tax change in % -52.25 -40.19 - - -30.53 24.22 -21.64
Income after tax -318.76 -209.36 -149.34 24.93 -77.06 -56.05 -73.96
Income after tax change in % -52.25 -40.19 - - -37.50 24.22 -21.64

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 436.69 58.68 29.79 41.29 48.43 31.93 30.89
Long-term liabilities per share 3.89 0.01 0.01 0.37 0.62 0.50 0.60
Equity 288.12 554.20 467.45 408.37 252.19 31.60 53.05
Equity change in % -48.01 18.56 14.47 61.93 698.06 -40.43 -49.15
Balance sheet total 724.82 612.88 497.24 449.66 300.61 63.53 83.94
Balance sheet total change in % 18.26 23.26 10.58 49.58 373.22 -24.32 -38.81

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 0.28 0.00 0.00 2.61 0.04 0.05 0.06
P/E ratio (year end quote, basic EPS) - - - 47.10 - - -
P/E ratio (year end quote, diluted EPS) - - - 47.10 - - -
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 39.75 90.42 94.01 90.82 83.89 49.74 63.20
Debt ratio in % 60.25 9.58 5.99 9.18 16.11 50.26 36.80

Syndax Pharmaceuticals Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Botwood Nicholas A.J. 05/15/2025 11,765.00 35,165.00 9.00 Buy No
Metzger Michael A 03/13/2025 6,074.00 306,195.00 7.20 Buy No
Metzger Michael A 03/03/2025 7,814.00 300,121.00 15.05 Sell No
Metzger Michael A 03/03/2025 7,814.00 307,935.00 7.20 Buy No
Gallagher Neil 02/09/2025 4,618.00 85,095.00 15.50 Sell No
Metzger Michael A 02/09/2025 13,288.00 300,121.00 15.50 Sell No
Goldan Keith A. 02/09/2025 3,777.00 90,746.00 15.50 Sell No
Huber Martin H. Jr. 02/04/2025 25,000.00 74,000.00 n/a Buy No
Legault Pierre 02/04/2025 25,000.00 90,000.00 n/a Buy No
Jarrett Jennifer 02/04/2025 25,000.00 90,000.00 n/a Buy No
Katkin Keith 02/04/2025 25,000.00 90,000.00 n/a Buy No
Rizo Aleksandra 02/04/2025 25,000.00 25,000.00 n/a Buy No
Podlesak Dennis 02/04/2025 50,000.00 191,763.00 n/a Buy No
Meury William 02/04/2025 25,000.00 90,000.00 n/a Buy No
Goldan Keith A. 02/04/2025 23,400.00 94,523.00 n/a Buy No
Goldan Keith A. 02/04/2025 18,500.00 71,123.00 n/a Buy No
Metzger Michael A 02/04/2025 89,000.00 313,409.00 n/a Buy No
Metzger Michael A 02/04/2025 60,500.00 224,409.00 n/a Buy No
Meury William 02/06/2024 17,000.00 65,000.00 n/a Buy No
Gallagher Neil 02/06/2024 34,688.00 34,688.00 n/a Buy No
Podlesak Dennis 02/06/2024 34,000.00 141,763.00 n/a Buy No
Gallagher Neil 02/06/2024 13,125.00 47,813.00 n/a Buy No
Morrison Briggs 08/08/2023 52,855.00 17,836.00 18.27 Sell No
Morrison Briggs 08/08/2023 52,855.00 70,691.00 8.77 Buy No
Meury William 08/01/2023 24,000.00 48,000.00 20.46 Sell No

Syndax Pharmaceuticals Dividend Calendar

Date Name Dividend *yield Currency
2024 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2023 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2022 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2021 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2020 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2019 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2018 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2017 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2016 Syndax Pharmaceuticals Inc 0.00 0.00 USD
2015 Syndax Pharmaceuticals Inc - - USD
2014 Syndax Pharmaceuticals Inc - - USD
2013 Syndax Pharmaceuticals Inc - - USD
2012 Syndax Pharmaceuticals Inc - - USD
2011 Syndax Pharmaceuticals Inc - - USD
*Yield of the Respective Date

Syndax Pharmaceuticals Calendar

Event Estimate Info Date
Earnings Report -1.000 USD Q2 2025 Earnings Release 08/11/2025
Earnings Report -0.921 USD Q3 2025 Earnings Release 11/11/2025
Earnings Report -0.864 USD Q4 2025 Earnings Release 03/09/2026
Earnings Report -0.890 USD Q1 2026 Earnings Release 05/11/2026

Syndax Pharmaceuticals Past Events

Event Actual EPS Info Date
Annual General Meeting -3.720 USD Annual General Meeting 05/14/2025
Earnings Report -0.980 USD Q1 2025 Earnings Release 05/05/2025
Earnings Report -1.100 USD Q4 2024 Earnings Release 03/03/2025
Earnings Report -0.980 USD Q3 2024 Earnings Release 11/05/2024
Earnings Report -0.800 USD Q2 2024 Earnings Release 08/01/2024
Annual General Meeting -2.980 USD Annual General Meeting 05/15/2024
Earnings Report -0.850 USD Q1 2024 Earnings Release 05/08/2024
Earnings Report -1.000 USD Q4 2023 Earnings Release 02/27/2024
Earnings Report -0.730 USD Q3 2023 Earnings Release 11/02/2023
Earnings Report -0.640 USD Q2 2023 Earnings Release 08/03/2023
Annual General Meeting -2.460 USD Annual General Meeting 05/17/2023
Earnings Report -0.590 USD Q1 2023 Earnings Release 05/08/2023
Earnings Report -0.620 USD Q4 2022 Earnings Release 02/28/2023
Earnings Report -0.580 USD Q3 2022 Earnings Release 11/03/2022
Earnings Report -0.620 USD Q2 2022 Earnings Release 08/08/2022
Annual General Meeting 0.480 USD Annual General Meeting 05/11/2022
Earnings Report -0.630 USD Q1 2022 Earnings Release 05/09/2022
Earnings Report 1.860 USD Q4 2021 Earnings Release 03/01/2022

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
6
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
OSZAR »